Immunotherapy for cSCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Treatment Options for Locally Advanced cSCC

Clinical Features and Diagnosis

Precancerous Actinic Keratoses

Squamous Cell Carcinomas

Advanced cSCC

Role of Practitioners in Disease Identification

Risk Factors

Risk Factors to Watch

Considerations for Therapy

Current Treatment Options

Which Patients Are Candidates for Immunotherapy?

How Do Risks Factors Affect Pathophysiology?

Overview of Immune Checkpoint Response

Immune Checkpoint Pathway

Immune Checkpoint Blockade

Rationale for Checkpoint Inhibitor Studies

Phase 1: Cemiplimab (REGN2810) Study Design

Phase 1: Cemiplimab (REGN2810) Patient Population and Response

Phase 2 Cemiplimab

Ongoing Checkpoint Inhibitor Trials in cSCC

Concluding Remarks

Abbreviations

Abbreviations (cont)